Department of Community Medicine, Kempegowda Institute of Medical Sciences (KIMS), Bangalore, India.
Community Processes and Comprehensive Primary Health Care division, National Health Systems Resource Centre, New Delhi, India.
Hum Vaccin Immunother. 2021 Aug 3;17(8):2554-2559. doi: 10.1080/21645515.2021.1883388. Epub 2021 Feb 23.
: World Health Organization has recommended that in healthy persons with category III exposures, who receive wound care and rabies immunoglobulin infiltration, a vaccine regimen consisting of 4 doses administered intramuscularly on days 0, 3, 7, and 14 can be used as an alternative to the 5-dose intramuscular regimen.: To assess the clinical safety and immunogenicity of rabies vaccine administered as 4-dose Essen intramuscular regimen for post-exposure prophylaxis.: A non-randomized, comparative, controlled study was conducted at the anti-rabies clinic, KIMS Hospital and Research Center, Bangalore, India. The study subjects were divided into study group i.e., 4-dose intramuscular regimen, and control group i.e., 5-dose intramuscular regimen, and were given post-exposure prophylaxis. All subjects were followed for any adverse drug events. Rabies virus neutralizing antibodies was determined on day 14, 90 & 180 at the WHO collaborating center, NIMHANS, Bangalore, India to assess the immunogenicity.: The present study included 70 adult animal bite victims, 35 each in study group and control group. The incidence of ADEs was 7.8% in 4-dose Essen group and 7.0% in 5-dose Essen group;the difference between them was not significant ( > .05). Similarly, all the subjects in both the groups had protective antibody titers of ≥ 0.5 IU/mL (100% seroprotective) from day 14 till day 180; the difference between two groups was also not significant ( > .05).: The 4-dose intramuscular Essen post-exposure prophylaxis regimen was found to be clinically safe and immunogenic.
世界卫生组织建议,对于类别 III 暴露的健康人群,在接受伤口护理和狂犬病免疫球蛋白浸润后,可以使用包含 4 剂肌肉注射的疫苗方案,在 0、3、7 和 14 天进行,作为 5 剂肌肉注射方案的替代方案。
评估狂犬病疫苗以 4 剂 Essen 肌肉内方案用于暴露后预防的临床安全性和免疫原性。
在印度班加罗尔的 KIMS 医院和研究中心的狂犬病诊所进行了一项非随机、对照、对照研究。研究对象分为研究组(即 4 剂肌肉内方案)和对照组(即 5 剂肌肉内方案),并给予暴露后预防。所有受试者均随访任何不良药物事件。在印度班加罗尔的 NIMHANS,世界卫生组织合作中心,在第 14、90 和 180 天测定狂犬病病毒中和抗体,以评估免疫原性。
本研究包括 70 名成年动物咬伤受害者,每组 35 名。4 剂 Essen 组的 ADE 发生率为 7.8%,5 剂 Essen 组为 7.0%;两者之间的差异无统计学意义(>.05)。同样,两组所有受试者的保护性抗体滴度均从第 14 天到第 180 天≥0.5 IU/ml(100%血清保护性);两组之间的差异也无统计学意义(>.05)。
4 剂肌肉内 Essen 暴露后预防方案被认为是安全且具有免疫原性的。